These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Reply: applying cluster analysis to data of previously published chronic heart failure trials: systems biology and clinical phenotypes of heart failure syndrome. Ahmad T; Felker GM J Am Coll Cardiol; 2015 Mar; 65(12):1270-1271. PubMed ID: 25814240 [No Abstract] [Full Text] [Related]
43. Reply: applying cluster analysis to data of previously published chronic heart failure trials. Francis GS; Cogswell R; Thenappan T J Am Coll Cardiol; 2015 Mar; 65(12):1270. PubMed ID: 25814241 [No Abstract] [Full Text] [Related]
44. Systems biology and clinical phenotypes of heart failure syndrome. Louridas GE; Lourida KG J Am Coll Cardiol; 2015 Mar; 65(12):1269-1270. PubMed ID: 25814239 [No Abstract] [Full Text] [Related]
45. The heterogeneity of heart failure: will enhanced phenotyping be necessary for future clinical trial success? Francis GS; Cogswell R; Thenappan T J Am Coll Cardiol; 2014 Oct; 64(17):1775-6. PubMed ID: 25443697 [No Abstract] [Full Text] [Related]
46. MicroRNA biomarkers for failing hearts? Mayr M; Zampetaki A; Kiechl S Eur Heart J; 2013 Sep; 34(36):2782-3. PubMed ID: 23886919 [No Abstract] [Full Text] [Related]
48. Multidimensional Approach of Heart Failure Diagnosis and Prognostication Utilizing Cardiac Imaging with Biomarkers. Kim IC; Yoo BS Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741176 [TBL] [Abstract][Full Text] [Related]
49. Cardiac protection induced by urocortin-2 enables the regulation of apoptosis and fibrosis after ischemia and reperfusion involving miR-29a modulation. Mayoral-González I; Calderón-Sánchez EM; Galeano-Otero I; Martín-Bórnez M; Gutiérrez-Carretero E; Fernández-Velasco M; Domenech N; Crespo-Leiro MG; Gómez AM; Ordóñez-Fernández A; Hmadcha A; Smani T Mol Ther Nucleic Acids; 2022 Mar; 27():838-853. PubMed ID: 35141045 [TBL] [Abstract][Full Text] [Related]
50. Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta-analysis. Kovács DK; Farkas N; Soós A; Hegyi P; Kelava L; Eitmann S; Schekk A; Molnár Z; Erőss B; Balaskó M Clin Transl Sci; 2021 Nov; 14(6):2461-2473. PubMed ID: 34378854 [TBL] [Abstract][Full Text] [Related]
52. Redefining biomarkers in heart failure. Correale M; Monaco I; Brunetti ND; Di Biase M; Metra M; Nodari S; Butler J; Gheorghiade M; Heart Fail Rev; 2018 Mar; 23(2):237-253. PubMed ID: 29511896 [TBL] [Abstract][Full Text] [Related]
53. Plasma endothelin-1-related peptides as the prognostic biomarkers for heart failure: A PRISMA-compliant meta-analysis. Zhang CL; Xie S; Qiao X; An YM; Zhang Y; Li L; Guo XB; Zhang FC; Wu LL Medicine (Baltimore); 2017 Dec; 96(50):e9342. PubMed ID: 29390406 [TBL] [Abstract][Full Text] [Related]
54. Hypertrophy of neurons within cardiac ganglia in human, canine, and rat heart failure: the potential role of nerve growth factor. Singh S; Sayers S; Walter JS; Thomas D; Dieter RS; Nee LM; Wurster RD J Am Heart Assoc; 2013 Aug; 2(4):e000210. PubMed ID: 23959444 [TBL] [Abstract][Full Text] [Related]
55. Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Pulakat L; DeMarco VG; Ardhanari S; Chockalingam A; Gul R; Whaley-Connell A; Sowers JR Am J Physiol Regul Integr Comp Physiol; 2011 Oct; 301(4):R885-95. PubMed ID: 21813874 [TBL] [Abstract][Full Text] [Related]